Synairgen (LON:SNG) Trading Down 18% – Here’s What Happened

Shares of Synairgen plc (LON:SNG) traded down 18% during trading on Monday . The stock traded as low as GBX 2.01 ($0.02) and last traded at GBX 2.01 ($0.02). 298,391 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 2,293,365 shares. The stock had previously closed at GBX 2.45 ($0.03).

Synairgen Price Performance

The firm’s fifty day moving average price is GBX 3.06 and its 200 day moving average price is GBX 3.75. The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09. The stock has a market cap of £4.05 million, a PE ratio of -67.00 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).